Docoh
Loading...

Thu. 4 Nov 2021, 7:48am ETBenzinga
In: Biotech, News, FDA, General

Two oral presentations highlighting updated results of PV patients on rusfertide achieving hematocrit control while essentially eliminating phlebotomy
Additional abstracts to be presented at ASH, providing further clinical and pre-clinical rusfertide data in PV as well as new pharmacology data for rusfertide in HH

NEWARK, Calif., Nov. 4, 2021 /PRNewswire/ -- Protagonist Therapeutics, Inc. (NASDAQ:PTGX) ("Protagonist" or "the Company") today announced that two abstracts highlighting updated data from its Phase 2 study of rusfertide in polycythemia vera (PV) have been selected for oral presentations at the American Society of Hematology (ASH) 2021 Annual Meeting taking place December 11-14, 2021. An additional three abstracts on rusfertide in PV and hereditary hemochromatosis (HH) have been accepted as poster presentations at ASH.

"We are delighted to have the opportunity to present further evidence of rusfertide's potential to improve outcomes in polycythemia vera and other diseases related to iron dysregulation," said Dinesh V. Patel, PhD, President and Chief Executive Officer of Protagonist. "Data included in these oral presentations will provide important new information about how rusfertide may reduce the need for phlebotomy and control hematocrit levels and symptoms for patients suffering from PV. The data we share at ASH this year will serve as a valuable springboard for further advancement of our rusfertide clinical programs, including the initiation of a Phase 3 clinical trial of rusfertide in PV in the first quarter of 2022."

Details for ASH 2021 oral presentations are as follows:

Title: "Rusfertide (PTG-300) Controls Hematocrit Levels and Essentially Eliminates Phlebotomy Requirement in Polycythemia Vera Patients"
Session Title: 634. Myeloproliferative Syndromes: Clinical and Epidemiological: Novel Therapies for MPNs and JAK inhibitors for Myelofibrosis
Presentation Type: Oral
Presentation Date and Time: Sunday, December 12, 2021/Session Time: 9:30 AM - 11:00 AM/Presentation Time: 10:15 AM
Authors: Ronald Hoffman, MD, Marina Kremyanskaya, MD, PhD, Yelena Ginzburg, MD, Andrew Kuykendall, MD, Naveen Pemmaraju, MD, Abdulraheem Yacoub, MD, Jay Yang, MD, Suneel Gupta, PhD, Frank Valone, MD, Sarita Khanna, PhD and Srdan Verstovsek, MD, PhD

Title: "Rusfertide (PTG-300) Induction Therapy Rapidly Achieves Hematocrit Control in Polycythemia Vera Patients without the Need for Therapeutic Phlebotomy"
Session Title: 634. Myeloproliferative Syndromes: Clinical and Epidemiological: Novel Therapies for MPNs and JAK inhibitors for Myelofibrosis
Presentation Type: Oral
Presentation Date and Time: Session Date: Sunday, December 12, 2021/Session Time: 9:30 AM - 11:00 AM/Presentation Time: 10:45 AM
Authors: Yelena Ginzburg, MD, Kamini Kirubamoorthy, Sinari Salleh, MD, Sung-Eun Lee, MD, PhD, Jae Hoon Lee, MD, PhD, Veena Selvaratnam, MD, Suneel K Gupta, PhD, Frank Valone, MD, Sarita Khanna, PhD, Nishit Modi, PhD, Ronald Hoffman, MD and Lee Ping Chew, MD

Additional details for ASH 2021 poster presentations are as follows:

Title: "A Phase 3 Study of the Hepcidin Mimetic Rusfertide (PTG-300) in Patients with Polycythemia Vera"
Session Title: 634. Myeloproliferative Syndromes: Clinical and Epidemiological: Poster I
Presentation Type: Poster
Presentation Date and Time: Saturday, December 11, 2021/Presentation Time: 5:30 PM - 7:30 PM
Authors: Srdan Verstovsek, MD, PhD, Andrew Kuykendall, MD, Ronald Hoffman, MD, Yelena Ginzburg, MD, Naveen Pemmaraju, MD, Frank Valone, MD, Nishit Modi, PhD, Sarita Khanna, PhD, Paula G O'Connor, MD, Suneel K Gupta, PhD and Jean-Jacques Kiladjian, MD, PhD

Title: "Regulation of Iron Homeostasis and Efficacy of Rusfertide Analog Peptide in a Mouse Model for Polycythemia Vera"
Session Title: 102. Iron Homeostasis and Biology: Poster II
Presentation Type: Poster
Presentation Date and Time: Sunday, December 12, 2021/Presentation Time: 6:00 PM - 8:00 PM
Authors: Roopa Taranath, PhD, Li Zhao, MD, PhD, Jayanthi Vengalam, MS, Lawrence Lee, BS,
Tenny Tang, MS, Celino Dion, Ahu Su, BS, James Tovera, BS, Ashok Bhandari, PhD,
Xiaoli Cheng, PhD, Larry Mattheakis, PhD and David Y Liu, PhD

Title: "Rusfertide (PTG-300), a Hepcidin Mimetic, Maintains Liver Iron Concentration in the Absence of Phlebotomies in Patients with Hereditary Hemochromatosis"
Session Title: 102. Iron Homeostasis and Biology: Poster I
Presentation Type: Poster
Presentation Date and Time: Date: Saturday, December 11, 2021/Presentation Time: 5:30 PM -7:30 PM
Authors: Kris V. Kowdley, MD, Nishit B Modi, PhD, Frank Valone, MD, Victor Priego, MD, Christopher Ferris, MD, PhD, Frank Cole, MD, and Suneel Gupta, PhD

Full abstracts can be found on the ASH website at https://www.hematology.org/meetings/annual-meeting/abstracts